{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:09:45Z","timestamp":1789016985371,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Identifying and treating inflammation is a recommended atherosclerotic cardiovascular disease (ASCVD) prevention strategy. The practice of screening for and treating inflammation is unknown. This study examined screening for inflammation and treatment with colchicine among patients with established ASCVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the Epic COSMOS electronic health record (EHR) database, we compared adults with known ASCVD between two time frames: (1) 2023 (colchicine FDA approved for ASCVD prevention) until April 2026 and (2) September 2025 [American College of Cardiology (ACC) scientific statement released] until April 2026. We examined screening for inflammation and treatment of inflammation. Chi-square tests compared differences before and after the ACC scientific statement on inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study contained 13.5 million adults aged 18 years or older diagnosed within the EHR with ASCVD. Only 1.2% of the patients with ASCVD were on colchicine. The proportion of patients with known ASCVD who were screened to assess inflammation was also very low (3.1%). Among patients who had hs-CRP measurements, 65.3% had elevated levels. Additionally, even in light of documented inflammation, the proportion of patients with elevated documented inflammation are on colchicine was low but did increase after the ACC scientific statement from 2.1% to 2.9%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The evidence on inflammation and its role in ASCVD is substantial. Screening for inflammation and treatment of the inflammation pathway in patients with ASCVD is very low and not consistent with evidence-based practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1882786","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:29:39Z","timestamp":1789014579000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Screening for inflammation and treatment with colchicine in adults with known cardiovascular disease: an analysis of 13.5 million patients"],"prefix":"10.3389","volume":"13","author":[{"suffix":"III","given":"Arch G.","family":"Mainous","sequence":"first","affiliation":[{"name":"Department of Community Health and Family Medicine, University of Florida","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Community Health and Family Medicine, University of Florida","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A.","family":"Orlando","sequence":"additional","affiliation":[{"name":"Department of Community Health and Family Medicine, University of Florida","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e560","DOI":"10.1161\/01.CIR.0000148983.88334.80","article-title":"CDC\/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper","volume":"110","author":"Biasucci","year":"2004","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/01.cir.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American heart association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11883-012-0295-3","article-title":"Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?","volume":"15","author":"Ridker","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","year":""},{"key":"B11","year":""},{"key":"B12","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jacc.2025.08.047","article-title":"Inflammation and cardiovascular disease: 2025 ACC scientific statement: a report of the American college of cardiology","volume":"87","author":"Mensah","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","article-title":"Clinician\u2019s guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week","volume":"72","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious diseases society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","article-title":"A test in context: high-sensitivity C-reactive protein","volume":"67","author":"Ridker","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"Cardiovascular disease and risk management: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/ehjqcco\/qcaa045","article-title":"Cost-effectiveness of low-dose colchicine after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT)","volume":"7","author":"Samuel","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"B23","year":""},{"key":"B24","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/eurjpc\/zwaf302","article-title":"The efficacy and safety of low dose colchicine in atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"33","author":"Tucker","year":"2026","journal-title":"Eur J Prev Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"101622","DOI":"10.1016\/j.jacadv.2025.101622","article-title":"Potential impact of colchicine on atherosclerotic cardiovascular disease in the United States","volume":"4","author":"Buckley","year":"2025","journal-title":"JACC Adv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"108177","DOI":"10.1016\/j.amepre.2025.108177","article-title":"Are U.S. preventive services task force recommendations effective? An evaluation of the 2015 prediabetes\/diabetes recommendation","volume":"70","author":"Orlando","year":"2026","journal-title":"Am J Prev Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e2537041","DOI":"10.1001\/jamanetworkopen.2025.37041","article-title":"Statin out-of-pocket expenditures under private insurance vs medicaid after 2016 USPSTF","volume":"8","author":"Mosier","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1377\/hlthaff.2017.1104","article-title":"Diffusion of innovations theory, principles, and practice","volume":"37","author":"Dearing","year":"2018","journal-title":"Health Aff"},{"key":"B30","year":""}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1882786\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:29:40Z","timestamp":1789014580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1882786\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":30,"alternative-id":["10.3389\/fmed.2026.1882786"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1882786","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1882786"}}